Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LY 4052031

Next Previous
Drug Profile

LY 4052031

Alternative Names: LY-4052031

Latest Information Update: 05 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer; Solid tumours

Most Recent Events

  • 21 Apr 2025 Eli Lilly and Company terminates the phase I NEXUS-01 trial in Solid tumours (Metastatic disease, Late-stage disease and Second-line therapy and greater) in the US, UK, Australia, France, Japan, South Korea, Spain (IV), due to sponsor decision (NCT06465069)
  • 01 Jul 2024 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater) in United Kingdom, Spain, South Korea, South Korea, Japan, France, Australia (IV) (NCT06465069) (EudraCT2024-512927-36-00)
  • 01 Jul 2024 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT06465069) (EudraCT2024-512927-36-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top